CYP19A1 and breast carcinoma: Clinical studies showed that ESR1 mutations that promote ligand-independent activation (e.g., Y537S, D538G) occur predominantly in metastatic or advanced breast cancer patients who were previously treated with estrogen deprivation therapy, especially aromatase inhibitors.